October 24, 2018
Sanofi and Advent International announced on October 1, 2018, that they had completed the sale of Zentiva, Sanofi’s European generics business, to funds managed by Advent International for €1.9 billion, effective September 30, 2018.
Zentiva is a health care player providing access across Europe to a broad generics portfolio covering a multitude of therapeutic areas. Headquartered in Prague, Zentiva reaches over 40 million patients in 25 European countries. Zentiva’s manufacturing facilities in Prague and Bucharest work with partners to produce and distribute more than 350 million packs per year.
Sanofi and Advent International announced the beginning of exclusive negotiations in April 2018 and entered into a binding agreement on June 27, 2018.
The Weil team from the Paris office advising Sanofi includes Private Equity partners David Aknin and Arthur de Baudry d’Asson, Private Equity associate Alexandra Stoicescu, Private Equity/M&A associates Guillaume de Danne and Juliette Spaes, Antitrust/Competition partner Romain Ferla, Antitrust/Competition associate Anne-Laïla Abback, Private Equity counsel Marc Lordonnois and Tax associate Alexandre Groult.
Attorneys from other Weil offices in Europe include: Private Equity partner Barbara Jagersberger and Private Equity associates Manuel-Peter Fringer and Alexander Pfefferler in Munich; Private Equity partners Michael Francies and James Harvey, Technology & IP Transactions partner Barry Fishley, and Private Equity associates Richard Draper, Edoardo Troina and Manjinder Tiwana in London; Mergers & Acquisitions partners Karel Drevinek and Vladimir Kykal, and Mergers & Acquisitions associate Tomas Bayer in Prague; and Private Equity partner Lukasz Gasinski, Private Equity counsel Monika Kierepa and Private Equity associate Aleksandra Kabac in Warsaw.